welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Study Determining the Frequency of Duchenne Muscular Dystrophy and Late-onset Pompe Disease (VICTORIA)
study id #: NCT04120168
condition: Duchenne Muscular Dystrophy, Pompe Disease (Late-onset)
This is a multicenter prospective non-drug screening study. The working period is 12 months. There is no research product to be followed or used in the study.
Demographic data, medical and family histories of the patients included in the study will be collected at the first admission. The following laboratory values of the patients will be collected:
• Alanine Transaminase (ALT)
• Aspartate Transaminase (AST)
• Gamma Glutamyl Transferase (GGT)
• Creatine Phosphokinase (CPK)
• In addition, physical examination information and Abdominal USG and Liver Biopsy Results, if any, will be collected. Following the above scans, enzyme analysis for late-onset Pompe disease in boys and girls and adolescents with high CPK levels and molecular genetic tests for Duchenne muscular dystrophy in boys and adolescents with high CPK levels will be performed.
intervention: Laboratory Tests
mechanism of action: No pharmaceutical intervention
last updated: February 25, 2020
start date: April 1, 2019
estimated completion: March 2020
phase of development: N/A
size / enrollment: 1500
- Frequency of Duchenne muscular dystrophin in boys and adolescents [ Time Frame: 1 year ]
The endpoints of the study were to determine the frequency of Duchenne muscular dystrophin in boys and adolescents with unexplained transaminase elevation for at least 3 months and in late onset Pompe disease in girls and boys and to determine the demographic and clinical characteristics of these patients.
• Eligible Sexes: all
• 3 months -18 years old boys and girls
• Serum transaminase levels (serum ALT and / or AST levels> 1.52 upper limit of normal (ULN)) for at least 3 months
• The willingness of the patient and / or legal representative to sign the written consent form
• Patients less than 3 months
• Patients with a known history of liver disease
• Patients with a known history of muscle disease
• Patients with a known history of rheumatologic disease
• Patients with clinical history or physical examination findings that support the possibility of liver disease (Jaundice, variceal bleeding, hepatomegaly, splenomegaly, ascites)
• ICU patients
• Patients with known congenital anomalies
• Patients with organ failure
• Patients with elevated serum GGT, Total Bliribun or Direct Bilirubin levels
Evaluation of Muscle miRNA as Biomarkers in DystrophinopathiesDuchenne muscular dystrophy (DMD), cause...
Extracellular RNAs in Urine May Work as Biomarker for Duchenne and Myotonic Dystrophy PatientsExtracellular RNAs found in urine may be...
Glenn A. Walter, PhDGlenn Walter is a Professor in Physiolog...
Biomarker for Duchenne Muscular Dystrophy (BioDuchenne)International, multicenter, observationa...
A Review of MD STAR net’s Research Contributions to Pediatric-Onset Dystrophinopathy in the United States; 200...Population studies of rare disorders, su...